A study to assess the long term retention on treatment and long-term safety and tolerability of Triheptanoin in male and female participants with drug-resistant epilepsy

This clinical trial, titled "A study to assess the long term retention on treatment and long-term safety and tolerability of Triheptanoin in male and female participants with drug-resistant epilepsy," is a research study looking for volunteers to participate. The study is registered as ACTRN12615000406505. Participants should be at least 16 years of age. Both men and women may participate. You may be eligible if: - TRIP-E study (ACTRN12612000226808) for cross referencing purposes - Participants randomised in the TRIP-E study and who finished the treatment period with appropriate compliance with diet and study procedures. - Ability to give informed consent (Participant, parent or person responsible) - Females of childbearing potential must have a negative serum betahCG at Visit 1 and either abstain or use acceptable contraception for the duration of the trial. You may NOT be eligible if: - Participants with a severe intellectual handicap - History of major psychiatric morbidity (such as psychiatric illness requiring hospitalisation or history of psychosis or major depression) - Participants with history of substance abuse, eating disorders or irritable bowel syndrome - Females who are pregnant or breast feeding - Participants with disorders affecting medium and short chain fatty acid oxidation. Talk to your doctor to see if this trial is right for you. Your doctor can help you understand the possible benefits and risks of participating, and whether you meet all of the requirements. Clinical trials are an important way to help advance medical knowledge and potentially gain access to new treatments.